Corrigendum to “Neuroprotection by post-stroke administration of the slow-releasing hydrogen sulfide (H2S) donor AP39: Long-term functional, MRI, and molecular evidence in a rodent stroke model” [European J. Pharmacol. 1008 (2025) 178331]

IF 5.7 3区医学 Q1 PHARMACOLOGY & PHARMACY

European journal of pharmacology Pub Date : 2026-07-15 Epub Date: 2026-06-13 DOI:10.1016/j.ejphar.2026.179077

Bartosz Pomierny, Weronika Krzyżanowska, Alicja Skórkowska, Jakub Jurczyk, Katarzyna Przejczowska-Pomierny, Małgorzata Szafarz, Monika Marcinkowska, Zuzanna Guzda, Patrycja Rachwał, Eugene Kim, Michel Mesquita, Roberta Torregrossa, Matthew Whiteman, Lucyna Pomierny-Chamioło, Joanna Pera, Bogusława Budziszewska

引用次数: 0

查看原文本刊更多论文

“脑卒中后给予缓释硫化氢（H2S）供体AP39的神经保护作用：长期功能、MRI和分子证据在啮齿动物脑卒中模型中的应用”[j].中华医学杂志，2008,8(2025):178331。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of pharmacology 医学-药学

CiteScore

9.00

自引率

0.00%

发文量

572

审稿时长

34 days

期刊介绍： The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.